Hypertension: Contemporary Assessment and Management

The illustrated target reflects the ESC 2024 on-treatment framework when tolerated. Individual targets may differ.

This overview concerns adult hypertension. Pregnancy requires a separate diagnostic and treatment pathway.

Hypertension remains one of the most important modifiable determinants of cardiovascular disease worldwide. Its consequences extend well beyond an elevated blood pressure reading: persistent hypertension contributes to coronary artery disease, stroke, heart failure, atrial fibrillation, chronic kidney disease, cognitive decline, vascular disease, and premature mortality.

Modern hypertension management has therefore moved beyond a simple threshold-based approach. Contemporary care integrates accurate blood pressure measurement, confirmation with out-of-office monitoring, global cardiovascular risk, hypertension-mediated organ damage, lifestyle intervention, pharmacological treatment, adherence, and repeated reassessment.

Two major contemporary frameworks currently guide practice: the 2024 European Society of Cardiology guideline and the 2025 AHA/ACC Multisociety High Blood Pressure Guideline. Their terminology differs somewhat, but both emphasize earlier cardiovascular risk reduction, accurate measurement, combination therapy when appropriate, and individualized blood pressure targets.

Accurate Blood Pressure Measurement Comes First

Before labeling a patient as hypertensive—or intensifying therapy—the measurement itself must be reliable.

Blood pressure should be obtained using a validated upper-arm device, an appropriately sized cuff, standardized positioning, adequate rest before measurement, and repeated readings rather than relying on a single isolated value.

Measurement error is clinically important. Poor technique, inappropriate cuff sizing, insufficient rest, talking during measurement, or device-related issues can materially change recorded blood pressure and may lead either to unnecessary treatment or to under-treatment.

Home blood pressure monitoring and 24-hour ambulatory blood pressure monitoring are especially valuable when white-coat hypertension, masked hypertension, variable readings, treatment resistance, or discrepancies between office and home values are suspected.

The 2024 ESC guideline places particularly strong emphasis on confirming both diagnosis and treatment response with out-of-office blood pressure whenever feasible. The 2025 U.S. guideline likewise incorporates home monitoring into contemporary blood pressure management and cautions against relying on cuffless wearable devices until their accuracy is sufficiently validated.

How to Measure Blood Pressure at Home

Use a validated upper-arm monitor with the correct cuff size. Avoid smoking, caffeine and exercise for 30 minutes beforehand, empty your bladder and rest quietly for at least five minutes.

Sit with your back supported, feet flat and legs uncrossed. Support the bare arm at heart level and do not talk.

Take two readings at least one minute apart and record both. Follow the morning/evening schedule and number of monitoring days agreed with your clinician. Bring your record and monitor to your appointment when possible.

Do not change medication based on a single reading or a cuffless smartwatch estimate. [5]

Understanding Contemporary Blood Pressure Categories

An important source of confusion is that European and U.S. guidelines use different terminology.

ESC 2024

AHA/ACC 2025

When systolic and diastolic readings fall into different categories, use the higher category. These are office BP categories; diagnosis generally requires repeated measurements and appropriate confirmation.

Office BP diagnostic categories, thresholds for starting medication and on-treatment targets are distinct. Office thresholds should not be applied as identical thresholds for home measurements or ambulatory BP monitoring. [1,2]

These differences do not mean that one system considers cardiovascular risk unimportant below 140/90 mmHg. Both guidelines recognize that cardiovascular risk increases progressively across the blood pressure range and that patients with higher overall cardiovascular risk may benefit from intervention at lower blood pressure levels.

Confirm the Diagnosis and Assess the Cardiovascular Context

Hypertension should not be evaluated in isolation.

Initial assessment should address:

• duration and severity of blood pressure elevation

• family history

• smoking

• obesity and physical activity

• diabetes

• dyslipidemia

• chronic kidney disease

• cardiovascular disease

• sleep-disordered breathing

• medication and supplement use

• alcohol exposure

• symptoms suggesting secondary hypertension

Baseline evaluation commonly includes renal function, electrolytes, glucose or HbA1c, lipid profile, urinalysis or albuminuria assessment, and a 12-lead ECG.

Echocardiography can provide additional information when there is clinical suspicion of left ventricular hypertrophy, structural heart disease, heart failure, or other cardiac involvement.

Identifying hypertension-mediated organ damage is clinically important because cardiac, renal, cerebrovascular, retinal, and vascular involvement can substantially modify cardiovascular risk and treatment intensity.

Cardiovascular Risk Should Influence Treatment

The contemporary approach treats blood pressure as one component of total cardiovascular risk.

The 2025 AHA/ACC guideline uses PREVENT-CVD to estimate 10-year total cardiovascular disease risk, including ASCVD and heart failure. This is distinct from PREVENT-ASCVD used for lipid-treatment decisions. Pharmacological therapy is recommended for adults with confirmed average systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg and also for selected patients with systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg who have clinical cardiovascular disease, previous stroke, diabetes, chronic kidney disease, or a 10-year PREVENT-CVD risk ≥7.5%. [2] Official AHA source: Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management.

For lower-risk adults with stage 1 hypertension—systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg—and no other indication for immediate pharmacological treatment, medication is recommended if BP remains elevated after 3–6 months of lifestyle intervention. Treatment decisions use reliable measurements and confirmed averages, not an isolated reading. [2]

The ESC similarly integrates overall cardiovascular risk, established cardiovascular disease, kidney disease, diabetes, familial hypercholesterolemia, and hypertension-mediated organ damage when determining whether patients with elevated blood pressure should receive pharmacological therapy.

Medication-initiation thresholds: ESC 2024 [1] and AHA/ACC 2025 [2]. These are not the same as diagnostic categories or treatment targets.

Lifestyle Intervention Is Core Therapy

Lifestyle treatment is not merely an adjunct to medication.

Effective strategies include:

• achieving and maintaining a healthy body weight

• a DASH- or Mediterranean-style dietary pattern

• reducing dietary sodium

• increasing dietary potassium when clinically appropriate

• regular aerobic exercise

• resistance exercise

• reducing sedentary behavior

• limiting or eliminating excessive alcohol

• smoking cessation

• improving sleep

• stress management

For many patients, several interventions used together produce greater blood pressure reduction than a single lifestyle modification alone.

Potassium recommendations require individualization in patients with chronic kidney disease, hyperkalemia, or medications that increase serum potassium.

The ESC specifically encourages sodium reduction, adequate potassium intake, healthy weight, aerobic and resistance exercise, and limitation of alcohol consumption. The U.S. guideline similarly places lifestyle intervention at the foundation of treatment across the entire blood pressure spectrum.

What Blood Pressure Should We Target?

This is one of the most important areas of contemporary hypertension management.

European approach

The 2024 ESC guideline recommends an on-treatment systolic BP of 120–129 mmHg for most adults receiving blood-pressure-lowering medication, provided therapy is well tolerated.

The corresponding routine target range is generally 120–129/70–79 mmHg.

However, the target should be individualized in patients with:

• symptomatic orthostatic hypotension

• age ≥85 years

• moderate-to-severe frailty

• limited life expectancy

• poor treatment tolerance

• selected patients with major competing health risks

When the preferred target cannot be tolerated, the ESC recommends pursuing blood pressure that is as low as reasonably achievable rather than rigidly forcing a numerical goal.

U.S. approach

The 2025 AHA/ACC guideline establishes an overarching treatment goal of:

<130/80 mmHg

for most adults, while recognizing that goals need modification in selected patients such as those with limited life expectancy, institutional care needs, pregnancy, frailty, or increased susceptibility to treatment-related adverse effects.

The practical message is that modern hypertension treatment increasingly favors effective cardiovascular risk reduction while maintaining tolerability, safety, and patient-centered decision-making.

On-treatment targets should be interpreted within their guideline framework and individualized for tolerability, frailty and orthostatic hypotension. [1,2]

Pharmacological Treatment

Four major classes have strong evidence as first-line therapy:

• ACE inhibitors

• angiotensin receptor blockers

• long-acting dihydropyridine calcium-channel blockers

• thiazide or thiazide-like diuretics

Drug selection should account for comorbidities, renal function, electrolyte status, pregnancy potential, heart failure, coronary artery disease, diabetes, albuminuria, previous stroke, tolerability, and other clinical considerations.

Beta-blockers remain valuable when another indication is present, including angina, selected post-myocardial-infarction settings, heart failure with an evidence-based agent, or ventricular rate control in arrhythmias. Their use should reflect the specific indication, heart rate, conduction, ventricular function and tolerance.

They are generally not the preferred initial treatment for uncomplicated primary hypertension. They may also have a role in selected resistant-hypertension regimens. [1,2,3]

Do not combine an ACE inhibitor with an ARB for hypertension treatment. [1,2]

Combination Therapy and the Single-Pill Strategy

Most patients ultimately require more than one antihypertensive agent.

Modern guidelines increasingly favor early combination therapy, particularly when blood pressure is substantially above target.

The 2025 AHA/ACC guideline recommends two first-line agents from different classes for stage 2 hypertension and favors a single-pill fixed-dose combination when possible to improve adherence and accelerate blood pressure control.

Common evidence-based combinations include:

• ACE inhibitor or ARB + calcium-channel blocker

• ACE inhibitor or ARB + thiazide/thiazide-like diuretic

The ESC similarly favors an initial low-dose two-drug single-pill strategy for most patients with established hypertension, followed when needed by triple combination therapy.

Monotherapy remains reasonable in selected patients, particularly when hypertension is mild, blood pressure is close to target, the patient is very old or frail, symptomatic orthostatic hypotension is present, or medication tolerance is a major concern.

Single-pill combination recommendations are supported by the ESC 2024 and AHA/ACC 2025 guidelines. [1,2]

Hypertension in Chronic Kidney Disease and Diabetes

Hypertension, diabetes, and chronic kidney disease frequently coexist and markedly amplify cardiovascular risk.

ACE inhibitors or ARBs have an especially important role in patients with chronic kidney disease and clinically significant albuminuria, because of their renal and cardiovascular benefits.

Renal function and potassium should be monitored after initiating or titrating renin-angiotensin-system blockers, diuretics, or mineralocorticoid receptor antagonists.

The therapeutic goal is not simply to lower an office blood pressure reading, but to reduce cardiovascular events and slow progression of kidney disease while avoiding hyperkalemia, acute kidney injury, and symptomatic hypotension.

Resistant Hypertension: Confirm Before Escalating

Resistant hypertension deserves special attention.

The newly published 2026 ACC Expert Consensus Decision Pathway defines resistant hypertension as uncontrolled BP ≥130/80 mmHg despite at least three complementary antihypertensive classes at maximally tolerated doses—including a diuretic—or controlled blood pressure requiring four or more classes.

Before diagnosing true resistant hypertension, clinicians should systematically exclude pseudoresistance.

This requires assessment of:

• blood pressure measurement technique

• white-coat effect

• home or ambulatory BP

• medication adherence

• inadequate dosing

• suboptimal drug combinations

• interfering prescription medications

• NSAIDs and other over-the-counter agents

• stimulants and supplements

• excess sodium

• obesity

• alcohol

• sleep apnea

• secondary causes

Medication nonadherence is particularly important and may account for a substantial proportion of apparent resistant hypertension.

Stepwise Treatment of Resistant Hypertension

The standard three-drug foundation usually includes:

RAS blocker + long-acting dihydropyridine CCB + effective diuretic

Diuretic therapy should be optimized before escalating further. In appropriate patients, chlorthalidone or indapamide may provide more sustained blood pressure lowering than shorter-acting strategies.

When blood pressure remains uncontrolled, a mineralocorticoid receptor antagonist, particularly spironolactone when renal function and potassium permit, remains a preferred fourth-line strategy.

If spironolactone cannot be tolerated, alternatives may include eplerenone or other agents selected according to the patient’s clinical profile.

A 2026 update

The 2026 ACC pathway also reflects the rapidly evolving therapeutic landscape. It discusses newer pharmacological options and device-based approaches for carefully selected patients with confirmed true resistant hypertension after optimization of conventional treatment.

These therapies should not replace accurate diagnosis, adherence assessment, lifestyle treatment, appropriate diuretic therapy, or standard multidrug therapy. Their use is best considered in collaboration with clinicians experienced in hypertension management.

Resistant-hypertension expert consensus pathway: [3].

Renal Denervation

Renal denervation has re-emerged as a potential therapeutic option for selected patients with difficult-to-control or resistant hypertension.

Contemporary guidance does not position renal denervation as a replacement for lifestyle modification or pharmacological treatment.

Rather, it may be considered after confirmation of persistent hypertension, exclusion of pseudoresistance and secondary causes, and careful discussion of benefits, limitations, procedural risks, patient preference, and alternatives.

The 2025 U.S. guideline and 2026 ACC pathway emphasize a multidisciplinary and shared decision-making approach when renal denervation is being considered.

Secondary Hypertension

A secondary cause should be considered particularly when hypertension is:

• resistant

• unusually severe

• abrupt in onset

• developing at a young age

• suddenly worsening after previously good control

• associated with spontaneous or diuretic-induced hypokalemia

• accompanied by renal dysfunction or suggestive endocrine features

Important causes include:

• primary aldosteronism

• renal parenchymal disease

• renovascular hypertension

• obstructive sleep apnea

• thyroid disease

• pheochromocytoma/paraganglioma

• Cushing syndrome

• primary hyperparathyroidism

• medication- or substance-related hypertension

Primary aldosteronism deserves particular attention because it is more common than historically appreciated and is especially relevant in resistant hypertension.

The 2025 Endocrine Society guideline conditionally suggests screening all individuals with hypertension for primary aldosteronism, with implementation depending on resources, expertise and feasibility.

Screening is particularly important in resistant hypertension and other high-suspicion presentations. Normal potassium does not exclude the condition.

Assessment includes aldosterone, renin and their ratio, with potassium and medication effects considered during interpretation. Patients should not stop antihypertensive treatment independently to prepare for testing. [4]

Older Adults, Frailty and Orthostatic Hypotension

Age alone should not automatically lead to therapeutic inertia.

The ESC supports effective blood pressure lowering in fit older adults but emphasizes individualized treatment in patients ≥85 years, those with significant frailty, limited life expectancy, or symptomatic orthostatic hypotension.

Assess for orthostatic hypotension at the initial evaluation and when suggestive symptoms develop. After five minutes of seated or supine rest, measure BP at one minute and/or three minutes after standing. A fall of at least 20 mmHg systolic or 10 mmHg diastolic meets the BP criterion for orthostatic hypotension. Interpret the findings alongside symptoms and clinical context. [1]

The presence of orthostatic hypotension should prompt careful medication review and individualized management rather than automatic withdrawal of all antihypertensive therapy.

Severe Hypertension and Hypertensive Emergency

A very high blood pressure reading should be interpreted in clinical context.

Severe hypertension above 180/120 mmHg without acute target-organ injury does not automatically require rapid intravenous blood pressure reduction. The 2025 U.S. guideline recommends timely evaluation and adjustment or initiation of oral therapy in appropriate nonpregnant patients without acute organ damage.

By contrast, severe hypertension accompanied by acute neurological, cardiac, renal, retinal, or aortic injury represents a hypertensive emergency and requires immediate hospital-based evaluation and controlled blood pressure reduction.

Symptoms such as acute neurological deficit, severe chest pain, pulmonary edema, altered consciousness, or features suggesting acute aortic disease require urgent medical assessment.

If a home reading is above 180 systolic and/or 120 diastolic, repeat it after at least one minute if you have no emergency symptoms. If it remains very high, contact a healthcare professional promptly.

Chest pain, severe breathlessness, new weakness, speech difficulty, visual disturbance or collapse require emergency assessment. In Qatar, call 999. Do not delay emergency care to keep repeating measurements. [6]

A hypertensive emergency is defined by acute organ injury, not the number alone. Serious symptoms can require emergency care even below these thresholds. Do not attempt rapid BP reduction with extra medication unless specifically instructed. [1,2]

Long-Term Follow-Up

Hypertension is a chronic cardiovascular disorder, and treatment should evolve over time.

Follow-up should assess:

• office and home blood pressure

• medication adherence

• adverse effects

• renal function

• electrolytes

• cardiovascular risk factors

• target-organ damage

• lifestyle progress

• symptoms of hypotension

• treatment burden

• changes in comorbidities

Single-pill combinations, home BP monitoring, team-based care, telemedicine, and structured treatment protocols can help improve long-term control.

The 2026 ACC resistant-hypertension pathway places particular emphasis on overcoming therapeutic inertia and using multidisciplinary care and digital monitoring more effectively in complex patients.

A Contemporary Perspective

Modern hypertension management is not about treating a number in isolation.

It begins with reliable measurement, confirmation of the patient’s true blood pressure phenotype and assessment of total cardiovascular risk.

Lifestyle treatment remains foundational. Pharmacological therapy should be sufficiently intensive to achieve evidence-based targets while remaining tolerable and safe. Combination therapy—preferably simplified through single-pill regimens—has become increasingly central to contemporary practice.

Patients whose blood pressure remains uncontrolled require systematic evaluation for adherence, interfering factors and secondary causes before being labeled resistant.

Ultimately, successful hypertension treatment aims to prevent stroke, myocardial infarction, heart failure, atrial fibrillation, kidney disease and premature cardiovascular death—not merely to produce a lower reading in the clinic.